Aromatase inhibitor-induced arthralgia: A review

Annals of Oncology

Volumn 24, Issue 6, 2013, Pages 1443-1449

  Niravath, P ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aromatase inhibitors; Arthralgia; Breast cancer; Survivorship

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; COLECALCIFEROL; CYCLOOXYGENASE 2 INHIBITOR; DIURETIC AGENT; DULOXETINE; ESTROGEN RECEPTOR; EXEMESTANE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 6; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PREDNISOLONE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ARTHRALGIA; ARTHROPLASTY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HOT FLUSH; HUMAN; KIDNEY DISEASE; KINESIOTHERAPY; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOLYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT PLANNING; VAGINAL DRYNESS; VITAMIN DEFICIENCY;

AROMATASE INHIBITORS; ARTHRALGIA; BREAST CANCER; SURVIVORSHIP;

ANIMALS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; DISEASE MANAGEMENT; FEMALE; HUMANS; RISK FACTORS;

EID: 84878461493     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt037     Document Type: Article

References (51)

1. Siegel R, DeSantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62: 220-241.
2. SEER. SEER Stat Fact Sheets: Breast. 2010. http://seer.cancer.gov/statfacts/ html/breast.html#survival (1 October 2012, date last accessed).
3. Howell A, Cuzick J, Baum M et al. Results of the ATAC trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
4. Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009; 361: 766-776.
5. Coombes R, Hall E, Gibson L et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
6. Crew K, Greenlee H, Capodice J et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early stage breast cancer. J Clin Oncol 2007; 25: 3877-3883.
7. Sestak I, Sapunar F, Cuzick J. Aromtase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 2009; 27: 4961-65.
8. Miegg J, Morden J, Bliss J et al. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 2012; 13: 420-432.
9. Henry N, Giles J, Ang D et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008; 111: 365-372.
10. Campos S, Guastalla J, Subar M et al. A comparative study of exemestane versus anastrazole in patients with post-menopausal breast cancer with visceral metastases. Clin Breast Cancer 2009; 9: 39-44.
11. Rose C, Vtoraya O, Pluzanska A et al. An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003; 39: 2318-2327.
12. Dent S, DeValentin T, Vandermeer L et al. Long term toxicities in women with early stage breast cancer treated with aromatase inhibitors: data from a tertiary care center. Breast Cancer Res Treat 2006; 100: S190.
13. Partridge A, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrazole therapy among women with early stage breast cancer. J Clin Oncol 2008; 26: 556-562.
14. Nekhlyudov L, Li L, Ross-Degnan D et al. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat 2011; 130: 681-689.
15. Ziller V, Kalder M, Albert U et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009; 20: 431-436.
16. Sedjo R, Devine S. Predictors of non-adherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 2011; 125: 191-200.
17. Cuzick J, Sestak I, Cella D. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 2008; 9: 1143-1148.
18. Hadji P, Kieback D, Tams J et al. Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Ann Oncol 2012; 23: 2566-72.
19. Huober J, Cole B, Wu J et al. Symptoms of endocrine treatment and outcome: a retrospective analysis of the monotherapy arms of the BIG 1-98 trial. Paper presented at: 2011 ASCO Annual Meeting; June 2011; Chicago, IL.
20. Cecil R, Archer B. Arthritis of Menopause. JAMA 1925; 84: 75-79.
21. Magliano M. Menopausal arthralgia: Fact or Fiction. Maturitas 2010; 67: 29-33.
22. Ho S, Chan S, Yip Y et al. Menopausal symptoms and symptom clustering in Chinese women. Maturitas 1999; 33: 219-227.
23. Cirillo D, Wallace R, Wu L et al. Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum 2006; 54: 3194-3204.
24. Dawson-Basoa M, Gintzler A. Gestational and ovarian sex steroid antinociception: synergy between spinal kappa and delta opioid systems. Brain Res 1998; 794: 61-67.
25. Din O, Dodwell D, Wakefield R et al. Aromatase inhibitor induced arthralgia in early breast cancer: what do we know and how can we find out more? Breast Cancer Res Treat 2010; 120: 525-538.
26. Islander U, Jochems C, Lagerquist M et al. Estrogens in rheumatoid arthritis; the immune system and bone. Mol Cell Endocrinol 2011; 335: 14-29.
27. Cutolo M, Villaggio B, Seriolo B et al. Synovial fluid estrogens in rheumatoid arthritis. Autoimmunity Rev 2003; 3: 193-198.
28. Le Bail J, Liagre B, Vergne P et al. Aromatase in synovial cells from postmenopausal women. Steroids 2001; 66: 749-757.
29. Forsblad d'Elia H, Mattsson L, Ohlsson C et al. Hormone replacement therapy in rheumatoid arthritis is associated with lower serum levels of soluble IL-6 receptor and higher insulin-like growth factor 1. Arthritis Res Ther 2003; 5: R202-R209.
30. Ahmed M, Gaffen S. IL-17 in obesity and adipogenesis. Cytokine Growth Factor Rev 2010; 21: 449-53.
31. Petersen A, Pedersen B. The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154-62.
32. Santen R. Effect of endocrine therapies on bone in breast cancer patients. J Clin Endocrinol Metab 2011; 96: 308.
33. Morales L, Pans S, Paridaens R et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 2007; 104: 87-91.
34. Zhang Q, Tang D, Zhao H. Immunological therapies relieve aromatase inhibitor-related joint symptoms in breast cancer survivors. Am J Clin Oncol 2010; 33: 557-560.
35. Sestak I, Cuzick J, Sapunar F et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008; 9: 866-72.
36. Mao J, Su H, Feng R et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res Treat 2011; 13: R8.
37. Crew K, Capodice J, Greenlee H et al. Randomized, blinded, shamcontrolled trial of acupuncture for the management of AI associated joint symptoms in women with early stage breast cancer. J Clin Oncol 2010; 28: 1154-1160.
38. Briot K, Tubiana-Hulin M, Bastit L et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormonereceptor- positive breast cancer: the ATOLL study. Breast Cancer Res Treat 2010; 120: 127-134.
39. Khan Q, Reddy P, Kimler B et al. Effect of vitamin D supplementation on serum 25 hydroxy vitamin D levels, joint pains, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119: 111-118.
40. Heidari B, Shirvani J, Firouziahi A et al. Association between nonspecific skeletal pain and Vitamin D deficiency. Int J Rheum Dis 2010; 13: 340-346.
41. Bocca C, Bozzo F, Bassignana A et al. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 2011; 350: 59-70.
42. Na H, Oliynyk S. Effects of physical activity on cancer prevention. Ann N Y Acad Sci 2011; 1229: 176-83.
43. Hojman P, Dethlefsen C, Brandt C et al. Exercise-induced muscle-derived cytokines inhibit mammary cancer cell growth. Am J Physiol Endocrinol Metabol 2011; 301: E504-E510.
44. Galantino M, Desai K, Greene L et al. Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integr Cancer Ther 2011; 11: 313-320.
45. Kubo M, Onishi H, Kuroki S et al. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res 2012; 32: 2331-36.
46. Xepapadakis G, Ntasiou P, Koronarchis D et al. New Views on treatment of aromatase inhibitors induced arthralgia. Breast 2010; 19: 249-50.
47. Muslimani A, Spiro T, Chaudhry A et al. Aromatase Inhibitor related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms? Clin Breast Cancer 2009; 9: 34-38.
48. Henry N, Banerjee M, Wicha M et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer 2011; 117: 5469-75.
49. Boccardo F, Rubagotti A, Puntoni MGP et al. Switching to anastrazole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrazole Trial. J Clin Oncology 2005; 23: 5138-47.
50. Goss P, Ingle J, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-71.
51. Goss P, Ingle J, Ales-Martines J et al. Exemestane for breast cancer prevention in post-menopausal women. N Engl J Med 2011; 364: 2381-2391. Annals of Oncology reviews Volume 24